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Introduction
Alpha 1-antitrypsin (␣1AT) deficiency, one of the more common lethal hereditary disorders in Caucasians of European descent, is characterized by reducing serum levels of ␣1AT, a 52-kDa glycoprotein that functions as an antiprotease. 1 The deficiency state is caused by mutations of the ␣1AT gene, a pleiomorphic, 12.2-kb 7-exon gene. 2 Normal ␣1AT serum levels are 20-53 m;
3 various combinations of at least 17 different mutations of the ␣1AT gene are associated with an ␣1AT level Ͻ11 m and significant risk for developing emphysema. 4 A subset of mutations is associated with hepatitis and cirrhosis. 5 These latter mutations all involve the production of abnormal proteins: they do not include null mutations. The pathogenesis of the liver disease is thought to be due to the accumulation of an abnormal ␣1AT protein in hepatocytes, and is associated with the finding that certain mutations of the ␣1AT gene cause derangement in the protein's intracellular processing and defects in the protein's excretion, commonly associated with liver injury. 6 The molecular defect in the protease inhibitor (Pi)Z allele, the allele most commonly associated with liver injury, is a G to A transition resulting in a Glu to Lys substitution at amino acid 342. This mutation is thought to cause the variant protein to aggregate in the rough endoplasmic reticulum of the liver cells. 4, 6 Although several studies have focused on the delivery of the normal ␣1AT gene into hepatocytes or airway cells to restore normal ␣1AT production and to protect lung tissue, 7-9 these approaches do not affect the liver disease. It would appear that the best way to treat ␣1AT deficiency disease is to reduce the production of the endogenous mutant form of ␣1AT protein and to increase the synthesis of the normal protein. The reduction of ␣1AT expression can be achieved by several strategies, such as antisense, gene-specific ribozymes, ␣1AT transcription factor specific-inhibitors, or intracellular expression of antibody to the mutant form of the ␣1AT protein.
Recently, ribozymes have been targeted to a wide variety of substrates and tested in biological systems to achieve the inhibition of cellular gene expression or viral replication. [10] [11] [12] [13] [14] [15] Ribozymes have an advantage in the therapy of chronic disease since they are not degraded when the target RNA is cleaved, and therefore, theoretically they need not be produced at higher levels than the target transcript. By using a hammerhead ribozyme, we should be able to target the mutant form of ␣1AT mRNA by using ␣1AT guide sequences attached to the ribozyme catalytic core sequence. Furthermore, if we change the corresponding cloned wild-type ␣1AT cDNA GUC and guide region nucleotide sequences while maintaining the amino acid sequence, this modified 'wild-type' ␣1AT mRNA should be resistant to the ribozyme.
A major issue in designing adequate gene therapeutic approaches to diseases is the availability of an effective vector system that will both deliver the gene of interest to the target organ and allow for its adequate expression. One of our laboratories has recently engineered the simain virus (SV)40 so that it has become an effective transfer vector system. 16, 17 In the present study, we report the transduction of an effective ␣1AT ribozyme in this SV40 vector system to inhibit the expression of the ␣1AT gene in a human hepatoma-derived cell line. At the same time, we have constructed a modified ␣1AT cDNA that is capable of producing the normal ␣1AT protein, yet its RNA is resistant to ribozyme cleavage.
Results
To study the effects of ribozymes on the expression of ␣1AT in a human hepatoma-derived cell line, we transduced PLC/PRF/5 cells that actively produce ␣1AT with either retroviral or SV40 recombinant viruses. Both polymerase II and III promoters were employed to drive expression of the ribozymes.
In one series of studies, 18 retroviral vectors were used to transfer ribozymes. RNA was extracted from a pooled population of cells that had been tranduced with the retroviral vectors and selected with G418 for 3 weeks. Those studies indicated that whereas ribozyme expression driven by a tRNA promoter decreased ␣1AT mRNA expression by as much as 85%, no such effect on ␣1AT mRNA expression was found when the CMV promoter was used to drive ribozyme expression. The SV40 vector system was somewhat more effective in that ribozymes driven by a polymerase II promoter were effective when transduced with the new vector system. PLC/PRF/5 cells were transduced using three different SV40 constructs, each containing either AT204 or 589 ribozyme. One construct employed the AT204 ribozyme driven by the tRNA promoter, one used the AT589 ribozyme under the control of the SV40 early promoter, and the third used the AT589 ribozyme with the tRNA promoter. No selection was applied to these cells. Fortyeight hours following transduction, RNA was isolated from the unselected populations of cells and assayed by Northern blot hybridization analysis. ␣1AT mRNA levels were significantly decreased in cells infected with the recombinant viruses in which ribozyme expression were driven by either the SV40 early promoter or the tRNA promoter, whereas there was no difference in GAPDH expression ( Figure 1) .
Further studies were done with ribozyme AT589 constructs because they generated consistently high ribozyme activity. Figure 2 is a series of representative Northern blots of RNA isolated from an unselected population of cells 48 h following transduction with a control construct, SVCAT, or with vector constructs containing 589AT ribozymes. The blots demonstrate the effectiveness of the ribozymes and their selective and specific properties.
In addition, we employed the AT589 construct in experiments of longer duration to demonstrate the effectiveness of the construct over time. The PLC/PRF/5 cells were transduced with the SV(⌬).tAT589 construct, then RNA was extracted at days 2, 7 and 14 following transduction. Figure 3 demonstrates that the ribozyme effectively cleaved the ␣1AT mRNA after 2 weeks of infection despite the cells having a doubling time of 3 days. This suggests that the construct was integrated, although no proof of integration was demonstrated. Another alternative explanation is that the high MOI employed allows for episomal expression in daughter cells.
To compensate for the endogenous ␣1AT expression being reduced by the AT589 ribozyme, we modified the nucleotide sequences of the target site of AT589 in the full-length ␣1AT cDNA, without changing amino acid 
Cells were transduced with the SV(⌬).tAT589T viral construct for different times or were mock-infected; then mRNA was extracted and Northern blot hybridization undertaken as described in Materials and methods. Lane 1, mock-infected cells; 2, cells harvested 2 days after infection; 3, cells harvested 7 days after infection; 4, cells harvested 14 days after infection.
sequences, to create the modified ␣1AT cDNA that would be resistant to AT589 ribozyme cleavage. To test the effectiveness of this construct, we stably transfected the PLC/PRF/5 cell line with the modified ␣1AT cDNA construct in a retroviral vector under the control of the CMV promoter. When we then transduced this line with the SV40 vectors containing ribozymes, the endogenous ␣1AT mRNA expression was considerably decreased by the two AT589 ribozyme constructs. The 204 construct had little if any effect. There was no effect of the ribozymes on the modified ␣1AT mRNA (Figure 4a ). Transduction with a control construct, SV(⌬)CAT, perhaps slightly decreased the expression of the endogenous ␣1AT mRNA in this experiment, but not in other experiments (see Figure 2 ). The specific nature of the ribozymes was demonstrated again when GAPDH was employed as a control; no effect on GAPDH expression was found with any ribozyme. Densitometry scanning of the experiments confirmed that the 589AT ribozymes were effective in selectively affecting the endogenous ␣1AT, without having an effect on the modified species (Figure 4b ).
Densitometry scanning of three sets of experiments indicated that the SVP.AT589 construct (driven by the SV-40 early promoter) decreased ␣1AT expression by 70.8 ± 4.0% (mean ± s.e.m.). The SV(⌬).tAT589 construct (driven by the tRNA promoter) decreased ␣1AT expression by 74.8 ± 2.1%.
To demonstrate that the modified cDNA is capable of producing a wild-type protein, two cell lines (HeLa and NIH 3T3) that do not express any endogenous ␣1AT protein were transduced with an SV40-derived vector that contained the modified ␣1AT cDNA. Figure 5 is a Western blot that shows that the transduced cell lines produce a quantitatively and qualitatively similar ␣1AT protein product when compared to the wild-type protein in the PLC/PRF/5 cell line.
Discussion
The present study indicates that hammerhead ribozymes can be effectively used to inhibit expression of ␣1AT in a hepatoma-derived cell line. The inhibitory activity of the ribozymes seems to depend on the ability to provide a high level of ribozyme expression. Our findings, in these and other studies, demonstrate that the ribozymes were effective whether they were transduced using the standard retroviral vector system employing a selected population of stably transfected cells, or employing the novel SV40 vector system without selecting for transduced cells. In addition, our results show that it is possible to transduce a modified cDNA into hepatoma cells, and that the transcript which encodes for the wild-type ␣1AT protein is not susceptible to ribozyme cleavage. These results suggest that the use of a 'bifunctional' vector may be a possible approach for the prevention and treatment of ␣1AT deficiency.
Although ribozymes are now recognized as a powerful extension of the antisense approach to gene therapy by their ability to selectively cleave specific mRNA species, 10-15 most previous reports employing ribozymes showed their successful targeting only in single cell clones. [11] [12] [13] [14] In addition, most reports involve targeting viral transcripts, levels of whose expression may be affected by controlling the virus:cell ratio. [19] [20] [21] [22] There are very few reports that demonstrated adequate inhibition of an endogenous cellular transcript -especially one expressed at high levels, and especially in a mixed population of transduced cells. 10, 15 Two recent reports show the effectiveness of ribozymes in inhibiting the expression of the transgene in transgenic mice. 23, 24 The common thread in most of these reports is the necessity for ribozymes to be expressed at high levels in order to inhibit the target gene expression.
In our studies, we determined that a tRNA promoter was required for the adequate expression of the ribozyme when the retroviral vector was employed; ␣1AT expression was not inhibited when the CMV promoter was used. This most likely occurred because the tRNA promoter is probably the best promoter for transcribing short RNA species.
14,15,25,26 Although we do not demonstrate in this report that the tRNA promoter-driven constructs synthesized greater amounts of the ribozymes, that is our speculation. Another possible explanation is the difference between the polymerase II and III transcripts. Recently it was shown that modifications of the 3′ end of ribozymes dramatically affected the intracellular stability and cleavage efficiency. 25 The RNAs transcribed by RNA polymerase II have long poly (A) tails which may affect the structure of the ribozyme and subsequently disturb the effective association with target RNA and the cleavage reaction. In addition, retroviral transcripts are often generated from long terminal repeat (LTR) to LTR, 27, 28 providing very bulky flanking RNA sequences that may interfere with catalytic and/or binding activation.
It appears that in some ways the newly described SV40 vector system 16, 17 may be more efficient in transducing and expressing its transgene than the retroviral system. We were able to inhibit ␣1AT expression with recombinant SV40 employing either the SV40 early promoter or the tRNA promoter. What makes the finding more impressive is that the effect on ␣1AT expression occurred in an unselected population of cells. This contrasts with the experience with the retroviral system, where cells were selected by G418 resistance, and only successfully transduced cells were evaluated. Such selection was not used in the SV40 experiments; RNA was isolated from the entire population of cells 48 h after infection with recombinant SV40 vector. No attempt was made to select a subpopulation of transduced cells. Moreover, the SV40-derived vector was successful in inhibiting ␣1AT expression 2 weeks following transduction, suggesting an integration event in these rapidly proliferating cells.
The SV40 system appears to have significant potential as a vector for gene therapy. This expression system, which is described in greater detail in earlier reports, 16, 17 uses to advantage the ability of SV40 to express encoded genes in many cell types and in different animals, its ability to infect and to drive expression in non-dividing cells, the lack of any pathologic immune response evoked by transduced cells, the relatively small size of the viral genome, the availability of cell lines that express various portions of the SV40 genome, and the strong SV40 early promoter. This system has been remarkably successful in animal experiments in mediating stable, strong expression of a reporter gene whose product can be detected by both enzymatic and immunohistochemical means. Firefly luciferase was cloned into the SV40 vector to produce a recombinant virus, SVluc. This recombinant virus was used to infect cultured target cells in which luciferase was detected immunohistochemically. 16 SVluc was also used to infect BALB/c mice in vivo. 17 Following intravenous inoculation, stable luciferase activity was detected by immunohistochemical analysis of frozen section tissues and by luminometric assay. Levels of enzyme expression in liver and other organs were stable for the duration of the experiment, 1 year, 17 without evidence of inflammatory reaction to the luciferase-expressing cells.
In the present report, we have delineated the first steps in the inhibition of abnormal ␣1AT gene expression, as well as the synthesis of a normal gene product for the treatment of ␣1AT deficiency disease. It appears that SV40 provides a promising new vector technology for designing feasible gene therapy systems. Further experiments must show the ability of the system to function in an adequate in vivo model.
Materials and methods

Ribozyme design and cloning
The details of the construct and screening of functional ␣1AT ribozymes have been reported by us previously. 28 The ribozymes that target ␣1AT mRNA at 204 and 589 were selected for testing in the SV40-derived system. Briefly, each ribozyme is denoted by the nucleotide position of the first G of the target GUC triplet when the first A of the initiation codon AUG is numbered as 1. The sequences of the ribozymes are shown in Figure 6 . For the design of the ribozymes, 11 to 15 bases of antisence sequence against ␣1AT mRNA were flanked on both sides of the hammerhead motif to allow the ribozyme to associate with ␣1AT mRNA through their complementary sequences. For the construction of the ribozymes, two complementary oligonucleotides were synthesized on the DNA synthesizer model 392 (Applied Biosystems, Foster City, CA, USA). The ribozymes were synthesized by incubating two oligonucleotides to form a hemiduplex, and PCR amplifications were performed. Then the PCR products were cloned directly into the pT7Blue-T vector (Novagen, Madison, WI, USA) to generate plasmids pT7ATRzs, which contained each ribozyme under the control of the bacteriophage T7 promoter.
Construction of modified ␣1AT cDNA
The details of the construction of a modified ␣1AT cDNA which would be resistant to an ␣1AT ribozyme and yet code for normal ␣1AT protein, have been reported by us previously. 18 This modified cDNA has the third nucleotide mutated in the 589 region (GTC → GTG), and in the immediate 5′ and 3′ flanking region. It is shown in Figure 7 . Briefly, the full-length ␣1AT cDNA was cloned into pT7 Blue-T vector (Novagen) to generate pT7␣1AT by RT-PCR, employing RNA from Hep G2 cells. Then modified oligonucleotides were used as templates for the PCR reaction leading to the generation of the modified ␣1AT. The PCR products were then cloned into the pT7Blue-T vector, to generate PT7m␣1AT.
Retroviral vector
For construction of the retroviral construct which carries a modified ␣1AT cDNA, the 1.3 kb fragment of human full-length, modified ␣1AT cDNA was excised from pT7m␣1AT with XbaI and SmaI, and recloned into the XbaI-PvuII site of the pSP72 vector (Promega) to generate pSP72␣1AT. The modified ␣1AT cDNA was cut with BglII and XhoI, and cloned into the BamHI-BglII site of pSLXCMV 30 to generate pSLXCMVm␣1AT (Figure 8 ). Orientations and sequences of retroviral vectors were confirmed by DNA sequencing.
Cells and transfection
The human hepatoma-derived cell line PLC/PRF/5 and the retrovirus packaging cell line PA317 were grown in DMEM supplemented with 10% fetal bovine serum. Subconfluent PA317 cells were transfected with plasmid pSLXCMVM␣1AT by lipofectin (Gibco BRL, Gaithersburg, MD, USA) according to the manufacturer's instruction manual. After 48 h, medium containing recombinant retrovirus particles was collected, and PLC/PRF/5 cells were transduced with the recombinant virus for 48 h; then PLC/PRF/5 cells were selected with 1 mg/ml of G418 (Bibco BRL) for 3 weeks. G418-resistant clones were picked under microscopy and subjected to further analysis.
Construction of SV40-derivative viruses for transduction
The details of the construction and application of modified SV40 vectors for the purpose of gene transduction have been reported elsewhere by us. 16, 17 The procedure is described briefly here. The 5.24 kb SV40 genome, cloned as a BamHI fragment into pBR322, was the kind gift of Dr Janet Butel (Baylor College of Medicine). The viral genome was modified by excising the gene for large T antigen (Tag) as an AvrII-BclI fragment, and replacing it by a modified pGEM7 polylinker, whose Sp6 and T7 promoters were flanked by AvrII and BclI restriction sites, respectively. This procedure also excises the gene for the small T antigen, but leaves the SV40 early promoter and the SV40 polyadenylation signal intact. The late viral genes, VP1, VP2 and VP3, which encode capsid proteins, are also undisturbed in this construct. This modified SV40 genome, still in pBR322, was named pBSV(⌬T′).
To produce virus from this construct, the viral genome was excised from pBR322, gel purified and recircularized. It was then transfected into COS-7 cells (ATCC) for packaging. The COS-7 cells used for this procedure contain a copy of the SV40 genome that is deficient in that it is a deletion in the origin of replication. Thus, these cells supply the missing Tag in trans and permit the replication and packaging of the resultant Tag-deleted viruses. TC7 cells (a kind gift of Dr J Butel), lacking the viral genome, do not permit replication of Tag-deleted SV40 derivatives. 17 This system therefore does not depend upon the presence of helper virus, but relies on expression of Tag by the packaging cells.
After visual examination for virus-induced cytopathic effect showed that Ͼ50% of COS-7 cells have been infected with virus, virus was released from the cells by freezing and thawing, followed by sonication. Most of the infectious virus remained associated with the cell cytoskeleton. Virus was titrated by measuring the concentration of infectious units that can penetrate target cells by an in situ polymerase chain reaction. 31 In general, yields of infectious virus without further purification are 10 9 TCID 50 /ml. Concentration of virus to approximately 10 10 TCID 50 /ml was accomplished by discontinuous sucrose density ultracentrifugation. This procedure was performed according to the method of Rosenberg et al. 32 Briefly, culture medium containing the SV40 derivative viruses was mixed 1:10 with a solution of 10% Triton X-100 + 5% deoxycholate, and layered on to a discontinuous sucrose density gradient (20% sucrose/75% sucrose) and centrifuged at 65 000 g in an SW28 rotor in a Beckman ultracentrifuge. This procedure dissociates virus from the associated COS cell cytoskeleton. Virus concentrated at the interface between the two sucrose layers is recovered, then dialyzed versus normal saline to remove excess sucrose. These preparations are titrated before use. 31 The ribozyme constructs described above were cloned into the multiple cloning site of pBSV(⌬T′). These cloning procedures yielded two different types of ribozyme-containing plasmids: one in which ribozyme expression was driven by the SV40 early promoter, and another in which the tRNA promoter was used to drive ribozyme transcription. Replication-incompetent SV40 derivative viruses containing these ribozyme constructs were produced and titrated as described above. These vectors are shown in Figure 9 .
Recombinant viruses, containing the ribozymes under the control of either the tRNA or SV40 early promoter, were used to transduce PLC/PRF/5 cells at an MOI of either 10 or 100. In one experiment, the hepatoma cells were stably transduced with the modified ␣1AT cDNA, by the use of vector pSLXCMVm␣1AT before transduction with the SV40-derived vectors. Two days following the transduction, RNA was isolated from an unselected population of cells and evaluated by Northern blot hybridization analysis.
RNA analysis
Total RNA from PLC/PRF/5 cells transduced or nontransduced with viral constructs was extracted by a modification of the method of Chomczynski and Sacchi. 33 Messenger RNAs were detected by Northern hybridization analysis as previously described 34 employing a human ␣1AT cDNA probe; human fibronectin, human transferrin and glyceraldehyde dehydrogenase (GAPDH) 35 were employed as controls. Samples of 20 g of total RNA were denatured in buffer containing 0.5 mg/l glyoxal, 50% dimethyl sulfoxide, 10 mm phosphate, electrophoresced in 1% agarose gel, transferred to a GeneScreen filter (New England Nuclear, Boston, MA, USA), and baked for 2 h at 80°C. The filters were prehybridized and were subsequently hybridized under stringent conditions with cDNAs labeled with ␣-32 P-dCTP by a primer extension kit (Amersham, Arlington Heights, IL, USA). After hybridization, the filters were washed and the signals were visualized by autoradiography. Densitometry analysis of the membranes was undertaken with the use of a phosphorimager (Molecular Dynamics).
Western blot analysis
HeLa and NIH 3T3 cells were cultured in DMEM plus fetal calf serum. Then each cell line was infected with an SV40 viral construct containing the modified ␣1AT cDNA, SVCMVm␣1AT. Forty-eight hours following infection the unselected cells were harvested and protein extracted as previously described. Proteins were subjected to electrophoresis in 10% sodium dodecyl sulfate polyacrylamide gels and subsequently transferred to a Poly Screen (PVDF) membrane (Dupont). After the membrane was blocked with 5% non-fat dry milk, the specific protein expression was detected with rabbit polyclonal anti-human ␣1AT antibodies (Boehringer Mannheim, Indianapolis, IN, USA), using the Dupont Western blot chemiluminescence kit, with the manufacturer's suggested protocol.
